

Turning off protein could boost immunotherapy effectiveness on cancer tumors

July 31 2018



In the lab. Credit: Johns Hopkins Kimmel Cancer Center



Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy in the Johns Hopkins Kimmel Cancer Center discovered inhibiting a previously known protein could reduce tumor burdens and enhance the effectiveness of immunotherapy treatments.

In order to investigate the role of the Yes-associated protein, or YAP, in T-cells in the cancer setting, scientists used mice genetically engineered to lack YAP in several T-cell populations, including regulatory T-cells, known as Tregs. This was the first time the relationship between YAP and Tregs has been explored.

The study was published in *Cancer Discovery* on June 15, 2018.

Tregs are important for health, because they prevent <u>autoimmune</u> <u>diseases</u> but can be a major obstacle in the mounting of immune responses to tumors and immunotherapy. YAP can be found in a subset of those regulatory T-cells.

Scientists tested the antitumor effects of YAP inhibitors alone and in combination with immunotherapies. Their encouraging results showed YAP plays a role in the suppression of antitumor immunity by Tregs and demonstrated by turning off YAP's abilities, <u>tumor</u> killing with less restrained immune cells is possible.

Fan Pan, M.D., Ph.D., senior author of the study and associate professor of cancer immunology, said blocking YAP or the signaling pathways under its control boosted the effects of both a tumor vaccine and a checkpoint inhibitor (anti-PD1 antibody) to produce even stronger antitumor activity. He said the approach of therapeutically targeting YAP was effective over a broad scope of cancer types in mice.

Since Tregs are notorious for dampening the effectiveness of tumordirected immunity in cancer patients, this study's finding may pave the



way for a new and promising strategy to unleash the patient immune response from the stifling grip of suppressor cell control.

While Pan and study authors are optimistic that further work could lead to effective YAP-targeting immunotherapies for <u>cancer</u>, they pointed out therapies aimed at enhancing YAP activity may have potential use for the treatment of autoimmune diseases.

More information: Xuhao Ni et al, YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity, *Cancer Discovery* (2018). DOI: 10.1158/2159-8290.CD-17-1124

Provided by Johns Hopkins University School of Medicine

Citation: Turning off protein could boost immunotherapy effectiveness on cancer tumors (2018, July 31) retrieved 22 November 2023 from https://medicalxpress.com/news/2018-07-protein-boost-immunotherapy-effectiveness-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.